Las Vegas, NV -- (SBWIRE) -- 04/22/2013 -- Titan Pharmaceuticals, Inc (OTC:TTNP) made an announcement regarding the presentations underlining the Probuphine®. The presentations will be made at two approaching medical meetings. Probuphine® is a long-acting subdermal implant formulation of buprenorphine for the treatment of opioid dependence in adult patients.
44th Medical-Scientific Conference of American Society of Addiction Medicine (ASAM) will be held on 25 till 28 April in Chicago. M.D., Professor of Psychiatry, Walter Ling and Director at Integrated Substance Abuse Programs at the David Geffen School of Medicine at UCLA, will be presenting the results of Probuphine® phase 3 development program on 26 April, 2013, Friday at the meeting ‘Buprenorphine: New Formulations, Medication Combinations, Indications and Longitudinal Effects’, sponsored by National Institute on Drug Abuse (NIDA). The meeting will be held in two sessions, 10:30 a.m. and 2:30 p.m. CT.
Another upcoming meeting is American Psychiatric Association (APA) 166th Annual Meeting, which will be held on 18-22 May, 2013 in San Francisco. Executive Vice President and Chief Development Officer of Titan Pharmaceuticals, Katherine Glassman-Beebe, Ph.D., will be presenting “Buprenorphine Implants for the Maintenance Treatment of Opioid Dependence” on 20th May, 2013, Monday at 2 p.m. PT during NIDA Symposia 74: “Advances in Pharmacotherapies for Substance Use Disorders.”
To find out what OTCMAGIC projects forTitan Pharmaceuticals, Inc.,for both short term and long term please click here: TTNP
OTCMAGIC Spends all day scouring the markets for the next huge Penny Stock Winner. Investors have come to trust us for our up to date commentary on all hot stocks so please visit OTCMAGIC right now and see what it’s all about for yourself! At 30,000 Visitors a Month and growing rapidly OTCMAGIC is the hottest thing in Stock Picks!
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at http://OTCMagic.com/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)